New online platform to help pharmaceutical companies find, evaluate and manage drug partners

goBalto, an online drug development partnering site for the pharmaceutical development and drug manufacturing industry, announced today its new platform and website, goBalto.com. goBalto transforms the way drug-development partners are matched. The web-based platform enables members to quickly and efficiently find partners, share knowledge, and discover opportunities.

"U.S. and EU pharmaceutical companies are under pressure to reduce costs and boost efficiencies in the drug development process," said Jae Chung, founder & CEO, goBalto. "As a result, companies are increasingly looking towards outsourcing to help reduce costs. But it's challenging for companies to identify and evaluate drug service providers. goBalto is addressing this by creating an online resource where users can quickly find and evaluate drug service providers, resulting in improved transparency and better decision making."

goBalto incorporates the following key features for its members:

  • Search and browser tools to screen from more than 7,000 potential service providers (investigator sites, CMOs, CROs, and consultants) to help customers find the right partner
  • Lists of potential service providers based on technical capabilities, regulatory compliance, facilities, equipment, and more
  • Capability to rate companies and post comments on vendors
  • Functionality to post about projects and jobs specific to the pharmaceutical industry
  • Ability to make and share collections of vendors for each project
  • Easy to read vendor summary profiles, incorporating videos, images and the latest in Web 2.0 technologies

"In today's highly competitive marketplace, it's critical to be able to find quality partners that can reduce your costs of drug development and time-to-market," said Dr. Cary Queen, Co-Founder of Protein Design Labs. "The goBalto platform provides members with the transparency and ability to quickly identify and evaluate new partners via a rating system that includes rich vendor profiles."

"goBalto provides a great platform for showcasing our drug development and manufacturing capabilities to biotech and pharmaceutical companies around the globe," said Kiran-Mazumdar Shaw, Chairman and Managing Director of Biocon Limited. "The goBalto partnering website provides us with a highly cost-effective channel to reach our target customers compared to traditional options such as industry conferences and advertising."

According to market research company Kalorama, the market for contract manufacturing of prescription drugs exceeded $30 billion last year, a 10% increase over the previous year. "The sheer numbers of biologics in the pipeline are driving drug makers to outsource specialized production rather than build new plants," according to Kalorama.

"Most existing sites are "one-way" distributors of content from the publisher to the user," said Mr. Chung. "But users today are seeking a more collaborative platform. We're not only improving transparency, but incorporating the latest in Web social media tools to enable users to share their collective experiences on topics ranging from vendors to regions in which to conduct trials."

For further information, please visit:
http://www.gobalto.com

About Jae Chung, Founder and CEO
Jae Chung founded goBalto in October 2008. Prior to goBalto, he co-founded Celltrion, a contract biopharmaceutical group in Asia. As Celltrion's vice president of business development, he secured deals with Bristol-Myers Squibb and CSL, and has been credited with landing the largest biomanufacturing supply agreement in Asia to date. Before starting Celltrion in 2002, he was the co-founder of the venture capital firm, J. Stephen & Company Ventures, and a strategy consultant at McKinsey and Company.

About goBalto
goBalto is a dedicated online drug development partnering site for the pharmaceutical and drug manufacturing industry. Users can identify, evaluate, and manage drug-development partners from around the world. Incorporating the latest in Web 2.0 technologies, goBalto's platform enables users to distinguish their offerings by adding logos, images, videos, customer testimonials and post referrals from members. More than 7,000 service providers are currently listed.

Most Popular Now

COVID-19 can trigger self-attacking antibodies

Infection with the virus that causes COVID-19 can trigger an immune response that lasts well beyond the initial infection and recovery - even among people who had mild sy...

Stopping dementia at the nose with combination of …

Dementia is thought to occur when proteins called amyloid-β, tau, and α-synuclein accumulate in the brain and form oligomers. A research group from the Department of Tran...

Treatments in weeks, not months: Scientists develo…

An international team of scientists has created a plan for an accelerated pipeline for developing drug cocktails to battle the COVID-19 pandemic. The pipeline could speed...

COVID-19 - Omicron: resistant to most monoclonal a…

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant...

Scientists identify antibodies that can neutralize…

An international team of scientists have identified antibodies that neutralize omicron and other SARS-CoV-2 variants. These antibodies target areas of the virus spike pro...

Pfizer and BioNTech sign new global collaboration …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a new research, development and commercialization collaboration to develop a potential first mRNA-based v...

Novartis and Molecular Partners report positive to…

Novartis and Molecular Partners announced that Part A of the EMPATHY clinical trial(1) that compared single intravenous doses of ensovibep, a DARPin antiviral therapeutic...

Bayer and Mammoth Biosciences to collaborate on no…

Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, today announced a strategic collaboratio...

Amgen and Arrakis Therapeutics announce multi-targ…

Amgen (NASDAQ:AMGN) and Arrakis Therapeutics today announced a research collaboration focused on the discovery and development of RNA degrader therapeutics against a rang...

Leiden University Medical Center and Intravacc to …

Intravacc, a global leader in translational research and development of therapeutic vaccines and vaccines against infectious diseases, today announced a partnership with ...

New Vaxzevria data further support its use as thir…

Positive results from a preliminary analysis of an ongoing safety and immunogenicity trial (D7220C00001) showed that Vaxzevria (ChAdOx1-S [Recombinant]), when given as a ...

AstraZeneca and Ionis close agreement to develop a…

AstraZeneca has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. (Ionis) for eplontersen, formerly known as IONIS-TTR-LRX. ...